home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410e.zip
/
M94B0789.TXT
< prev
next >
Wrap
Text File
|
1994-11-11
|
3KB
|
46 lines
Document 0789
DOCN M94B0789
TI Increased survival of immunodeficient retrovirus infected mice treated
with lithium (Meeting abstract).
DT 9412
AU Gallicchio VS; Cibull ML; Hughes NK; Tse KF; Hematology and Oncology
Division, Department of Internal; Medicine, University of Kentucky
Medical Center, Lexington, KY; 40536
SO Proc Annu Meet Am Assoc Cancer Res; 35:A1824 1994. Unique Identifier :
AIDSLINE ICDB/94603528
AB Murine immunodeficiency virus disease (MAIDS) induced with LP-BM5 MuLV
shows many similarities to human HIV-infection. The etiological agent is
a defective MuLV capable of inducing disease with the aid of a helper
virus. Lithium (Li) influences numerous immunohematopoietic cell types
and cellular processes that involve cell proliferation and
differentiation. We report here results of in vivo studies investigating
the effect of Li in MAIDS. Virus control and Li-treated viral infected
C57BL6 mice were monitored for survival and development of MAIDS
pathology. Virus-infected mice were grouped to initiate Li (1 mmol)
daily as follows: (1) 7-days before virus; (2) 2-days before virus; (3)
at the same time as virus, and (4) 5-weeks post-virus inoculation. Daily
Li was continued during the study period. Following 36 wk of
observation, percent survival was as follows: virus controls, 0%; Li
7-days 100%; Li 2-days 90%; Li day-0 85%; and Li 5 weeks post-virus 80%.
Development of lymphoma in Li-treated virus infected mice was reduced
significantly as measured via ultrastructural, histopathological and
gross anatomical analysis as measured by thymus involvement,
lymphadenopathy and splenomegaly (gm): virus control, 1.21 +/- 0.21; Li
5-weeks post-virus, 0.48 +/- 0.03; Li day 0, 0.28 +/- 0.01; Li 2-days,
0.25 +/- 0.02; normal control 0.1 +/- 0.01 (P value less than 0.01).
Myeloid, erythroid and megakaryocyte hematopoietic progenitors were also
increased compared to virus infected controls. These studies indicate Li
is an efficacious treatment in modulating MAIDS and raises important
questions regarding its potential role in the pathophysiological
processes associated with retroviral infections.
DE Animal Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Drug
Administration Schedule Hematopoietic Stem Cells/DRUG EFFECTS/PATHOLOGY
Lithium/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
Lymphoma/COMPLICATIONS/PREVENTION & CONTROL Mice Mice, Inbred C57BL
Murine Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG
THERAPY/PATHOLOGY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).